author-photo

Charles Phelps

Janssen Pharmaceutica

22

Papers

550

Citations

Citation Trend

Filter By

Papers (13) Sort By

Journal Conference Others

Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma

2019 Leukemia
Show All
- Source
- Cite
- Save
Citations (64)
Quisinostat, bortezomib, and dexamethasone combination therapy for relapsed multiple myeloma

2016 Leukemia & Lymphoma
Show All
- Source
- Cite
- Save
Citations (17)
Sequence variants in patients with primary and acquired resistance to Ibrutinib in the phase 3 MCL3001 (RAY) trial

2016 Haematologica
Show All
- Source
- Cite
- Save
Citations (2)
Sequence variants in patients with primary and acquired resistance to ibrutinib in the phase 3 MCL3001 (RAY) trial.

2016 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (12)
11q Deletion (del11q) Is Not a Prognostic Factor for Adverse Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Ibrutinib: Pooled Data from 3 Randomized Phase 3 Studies

2016 Blood
Show All
- Source
- Cite
- Save
Citations (7)
Ibrutinib (I) plus bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): a 2-year follow-up of the HELIOS study.

2016 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (8)
Insights into the Management of Adverse Events in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Experience from the Phase 3 HELIOS Study of Ibrutinib Combined with Bendamustine/Rituximab

2015 Blood
Show All
- Source
- Cite
- Save
Citations (3)
Ibrutinib combined with bendamustine/rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): subgroup efficacy analyses from the HELIOS trial

2015 Leukemia & Lymphoma
Show All
- Source
- Cite
- Save
Citations (1)
Improvement of Quality of Response with Ibrutinib Plus Bendamustine/Rituximab Vs Placebo Plus Bendamustine/Rituximab for Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

2015 Blood
Show All
- Source
- Cite
- Save
Citations (1)
Ibrutinib combined with bendamustine/rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): safety analysis in the HELIOS trial

2015 Leukemia & Lymphoma
Show All
- Source
- Cite
- Save
Citations (1)